24.09.2018 | Nephrology - Original Paper | Ausgabe 11/2018
Clinical trial of the effects of coenzyme Q10 supplementation on
glycemic control and markers of lipid profiles in diabetic hemodialysis
patients
- Zeitschrift:
-
International Urology and Nephrology
>
Ausgabe 11/2018
- Autoren:
- Melika Fallah, Gholamreza Askari, Alireza Soleimani, Awat Feizi, Zatollah Asemi
Abstract
Purpose
The current study was conducted to determine the effects of coenzyme
Q10 (CoQ10) supplementation on glycemic control and markers of lipid profiles
risk in diabetic hemodialysis (HD) patients.
Methods
This randomized, double blind, placebo-controlled clinical trial was
performed among 60 diabetic HD patients. Subjects were randomly allocated into
two groups to take either 120 mg/day of CoQ10 supplements or placebo (n = 30 each group) for 12 weeks.
Results
After 12 weeks of intervention, CoQ10 supplementation, compared with
the placebo, resulted in a significant decrease in serum insulin concentrations
(− 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin
resistance (− 0.9 ± 2.1 vs. + 1.2 ± 3.0, P = 0.002), and significant increase in the quantitative insulin
sensitivity check index (+ 0.009 ± 0.01 vs. − 0.02 ± 0.05, P = 0.003). In addition, a trend toward a greater
decrease in serum triglycerides (− 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-cholesterol levels (− 0.9 ± 10 vs. + 3 ± 9,P = 0.078) was observed in the CoQ10
group compared to the placebo group. We did not observe any significant effect
of CoQ10 supplementation on fasting glucose, HbA1c and other lipid profiles
compared with the placebo.
Conclusions
Overall, our study supported that CoQ10 supplementation to diabetic
HD patients for 12 weeks had beneficial effects on markers of insulin
metabolism, but did not affect fasting glucose, HbA1c, and lipid profiles.
Clinical registration
http://www.irct.ir: IRCT2016081811763N30.